Promising

BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease

WAKEFIELD, Mass.--(BUSINESS WIRE)--Jul 10, 2007 - BusinessWeekpublished an article on July 6 discussing the race bypharmaceutical and biotechnology companies to be first to bring tomarket an effective angiogenesis treatment for cardiovasculardisease. While angiogenesis therapies are being pursued bySanofi-Aventis, Boston Scientific, Baxter, and Genzyme, amongothers, the article highlights a...

BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease

WAKEFIELD, Mass.--(BUSINESS WIRE)--Jul 6, 2007 - BusinessWeek todaypublished an article discussing the race by pharmaceutical andbiotechnology companies to be first to bring to market an effectiveangiogenesis treatment for cardiovascular disease. Whileangiogenesis therapies are being pursued by Sanofi-Aventis, BostonScientific, Baxter, and Genzyme, among others, the articlehighlights a very...

Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop

PRINCETON, N.J.--(BUSINESS WIRE)--Jun 28, 2007 - CytogenCorporation (NASDAQ: CYTO) reported updated data from a Phase 1dose escalation study evaluating QUADRAMET(R) (samarium Sm-153lexidronam injection) in combination with bortezomib (Velcade(R),Millennium Pharmaceuticals, Inc.) in patients with relapsedmultiple myeloma. Data from 33 patients were presented today in aposter titled, "Phase 1...

CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS

LOS ANGELES--(BUSINESS WIRE)--Jun 27, 2007 - CytRx Corporation(NASDAQ:CYTR), a biopharmaceutical company engaged in thedevelopment and commercialization of human therapeutics, todayannounced promising data from the six-month, open-label extensionof its completed Phase IIa clinical trial with arimoclomol in ALSvolunteers. While the clinical trial was not placebo-controlled,arimoclomol at a 1...

Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma

CHICAGO and REGENSBURG - June 21, 2007 - “In anaplasticastrocytoma, AP 12009 as a monotherapy is actually clearly superiorto temozolomide,” Prof. Albert Wong, M.D., StanfordUniversity, California, U.S.A. commented on the international PhaseIIb study with the TGF-beta 2-inhibitor AP 12009, under developmentby Antisense Pharma. Prof. Wong discussed the results of the studyin th...

Promising Data on Cognitive Effects of Safinamide in Early Parkinson's Disease

• Data presented at Movement Disorder Society’s 11thInternational Congress • Management of cognitive impairment in earlyParkinson’s disease patients is a critical unmet medicalneed Geneva, Switzerland, June 8, 2007 – Merck Serono S.A.(virt-x: SEO) and its partner Newron Pharmaceuticals S.p.a. (SWX:NWRN) announced today data, which suggest tha...

Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia

- Results from a Children's Oncology Group (COG) Study Presented atAmerican Society of Clinical Oncology Annual Meeting - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Immunomedics,Inc. , a biopharmaceutical company focused on developing monoclonalantibodies to treat cancer and other serious diseases, todayannounced that treatment with epratuzumab plus standardchemotherapy is feasible...

Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO

Clinical Benefit Shown in 35% of HER2-Positive Metastatic BreastCancer Patients HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated presented data from a Phase 1 clinicaltrial showing that alvespimycin, its second-generation Hsp90inhibitor, demonstrated promising antitumor activity andtolerability in combination with trastuzumab (Herceptin(R)) inpatient...

Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin

Investigational cancer drug Pertuzumab shows promising results inadvanced breast cancer when combined with Herceptin Phase IIIdevelopment initiated BASEL, Switzerland, June 4, 2007-Early clinical results fromRoche's trial of the exciting new cancer medicine pertuzumab, a HERdimerisation inhibitor, show substantial anti-tumour activity inpatients with pre-treated HER2 positive breast cance...

Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated presented data from a Phase 1 clinicaltrial showing that KOS-1584/R1645, an epothilone underco-development with Roche, demonstrated promising antitumoractivity and tolerability in patients with solid tumors.KOS-1584/R1645 showed activity in 32% of patients (13 of 41evaluable) including activity in pati...

Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO

Tanespimycin TIME Registration Program to Begin Third Quarter 2007 HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated presented data from a dose-escalatingPhase 1b clinical trial of its lead Hsp90 inhibitor, tanespimycin(KOS-953) in combination with bortezomib (Velcade(R)), showing ahigh degree of antitumor activity and tolerability in patients withmult...

Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer

- Data Support Rationale for Comprehensive Ongoing Phase 2 Programas Combination Agent with Standard Chemotherapies and Pivotal LungCancer Trial Scheduled to Begin Early Next Year - CHICAGO and SUNNYVALE, Calif. June 01, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announcedpromising preliminary results from an open-label Phase 2 clinicaltrial of Xcytrin(R) (motexafin gadoliniu...

Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers

- Company Planning to Initiate Phase 2 Trials in Colorectal Cancerand in Hormone-Refractory Prostate Cancer in Q307 - SOUTH SAN FRANCISCO, Calif., June 01, 2007/PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , abiopharmaceutical company focused on oncology, today announcedpromising results from an interim safety analysis of two Phase 1dose-escalating trials of picoplatin, a new ge...

Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241 in Patients With Advanced Solid Tumors

SEATTLE--(BUSINESS WIRE)--Jun 1, 2007 - Introgen Therapeutics, Inc.(NASDAQ:INGN) reported promising Phase 1/2 clinical data with INGN241, the Company's novel investigational mda-7/IL-24 tumorsuppressor agent, in patients with advanced solid tumors. The data (Abstract #380), which were presented today at theannual meeting of the American Society of Gene Therapy, showed thatin this 22-patie...

XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting

Trial Included One of the Most Challenging Patient PopulationsStudied of Any Drug-Eluting Stent (DES) Clinical Trial BARCELONA and MENLO PARK, Calif., May 22, 2007/PRNewswire-FirstCall/ -- XTENT, Inc. announces positive six-monthfollow-up data from the CUSTOM II clinical trial, which assessedthe safety and efficacy of the company's investigational CustomNX(R) drug-eluting stent (DES) syst...

IR BioSciences Announces Promising Data from Study of Its Compound Homspera

Data Suggests Homspera Shows Promise As an Adjuvant for Vaccinesagainst Avian Flu and Other Viruses SCOTTSDALE, Ariz., May 07, 2007 /PRNewswire-FirstCall/ -- IRBioSciences Holdings, Inc. announced today that preliminary datafrom its influenza vaccine adjuvant study being performed inconjunction with GenPhar Inc. indicates Homspera elevates hostimmune responsiveness above that induced by v...

Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimer's Drug

Samaritan Announces Positive Data in Nonclinical (IND) In- VitroStudies for Promising Alzheimer's Drug LAS VEGAS, May 3, 2007 (PRIME NEWSWIRE) -- SamaritanPharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs,is pleased to announce positive results were attained with itslate-stage preclinical/nonclinical testing of Caprospinol (SP-233),with well recognized in-vitro models....

Insmed Announces Promising Results From IPLEX Phase II Myotonic Muscular Dystrophy Clinical Study

RICHMOND, Va.--(BUSINESS WIRE)--May 3, 2007 - Insmed Inc.(Nasdaq:INSM) today announced positive results from a Phase IIinvestigator-sponsored study of the company's drug, IPLEX(TM), inpatients with myotonic muscular dystrophy (DM1). Preliminary results of the clinical study, being conducted atthe University of Rochester School of Medicine and Dentistry,showed that six months of treatment...

Targeting Specific Mutations Reveals Promising New Approach to Treating Genetic Disorders; Preclinical Data Published in Nature

PTC124 Targets Nonsense Mutations; Addresses Underlying Cause ofGenetic Disorders and Restores Protein Function SOUTH PLAINFIELD, N.J., April 23, 2007 /PRNewswire/ -- Newpreclinical data published online in the current edition of thejournal Nature show that PTC124, an investigational new drugdesigned to bypass nonsense mutations, was efficacious in apreclinical model of Duchenne muscular...

Biomira Selects PX-866 as Clinical Development Candidate and Presents Promising Preclinical Data at AACR

-IND filing expected by end of 2007- EDMONTON, April 16, 2007 /PRNewswire-FirstCall/ - Biomira Inc.today announced that it has selected PX-866 as its next clinicaldevelopment candidate. PX-866 is an inhibitor of thephosphatidylinositol-3-kinase (PI3 kinase)/ PTEN/AKT pathway, animportant survival signaling pathway that is activated in manytypes of human cancer, including glioblastoma. Pre...

Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimer's Research

In Vitro Assays Show rBChE Suppresses Amyloid PlaqueFormation ANNAPOLIS, Md., April 3, 2007 - PharmAthene, Inc., a leadingbiodefense company specializing in the development andcommercialization of medical countermeasures against chemical andbiological terrorism, announced today that new data from itsrecombinant butyrylcholinesterase (rBChE) research program wererecently presented...

PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimer's Research

In Vitro Assays Show rBChE Suppresses Amyloid Plaque Formation ANNAPOLIS, Md., April 03, 2007 /PRNewswire/ -- PharmAthene,Inc., a leading biodefense company specializing in the developmentand commercialization of medical countermeasures against chemicaland biological terrorism, announced today that new data from itsrecombinant butyrylcholinesterase (rBChE) research program wererecently pr...

Arpida Announces Promising Results of "First-In-Man" Studies With AR-709

High Concentrations Reached in Key Lung Compartments REINACH and BASEL, Switzerland, March 29, 2007/PRNewswire-FirstCall/ -- Arpida Ltd. today announced promisingresults of "first-in-man" studies with AR-709. These radiolabelledHuman Microdose studies included a total of 19 healthy malevolunteers. This groundbreaking study is the first ever using Microdosingfor the determination of...

ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent

Compound Could Be Utilized as an Adjuvant and Play Key Role in theTreatment of Influenza and Cancer SCOTTSDALE, Ariz., March 20, 2007 /PRNewswire-FirstCall/ --ImmuneRegen BioSciences, a wholly owned subsidiary of IRBioSciences Holdings, Inc. , announced today that data obtained bythe Company on its Substance P analog, Homspera, suggests that thecompound has potential value as a co-therape...

Intercell AG: Novel tuberculosis Vaccine Shows Promising Immunogenicity and Safety Profile

The Danish Statens Serum Institut (SSI) and Intercell from a phase I clinicaltrial with a tuberculosis (TB) subunit vaccine The vaccine is produced by SSI and contains Intercell’sadjuvant IC31™...